|
|
Post by cyn on Aug 20, 2015 12:57:38 GMT -5
bioexec, thanks for sharing the story about Roche, Gilead and Tamiflu...very appropriate case reminder. Yes, I too agree that it would be a "disaster" for Mnkd to go it alone.
Btw, does any one know the schedule and convening frequency of Mnkd-Sanofi joint steering committee? |
|
|
|
Post by bioexec25 on Aug 20, 2015 16:04:38 GMT -5
Cyn, I'm not certain but I believe it was quarterly reviews. May be monthly now that launch is ramping up.
|
|
|
|
Post by Chris-C on Aug 20, 2015 22:57:49 GMT -5
With respect Trend, how is this new thread much different from the general tone you created in the FWIW thread? It sounds to me like your hedgie friend created some doubt in your stated long position. I recommend the two threads be combined and labeled "Short thesis on viablity of the Sanofi-Mannkind partnership. Chris C My doubts in my long position have to do with the reality of pitiful script counts I see every Friday, and my recalculation of the market cap of Mannkind based on the pitiful script revenue and the lack of transparency about future Technosphere technology in terms of contributing to the valuation of the Company. I have to admit, I got sucked into all of the hype when we went spent countless days and weeks forecasting what Afrezza sales were going to be after approval, and how that was going to translate into a SP. Now I'm reverting to my prior life, when I was a bean-counter, so I'm looking close at the real numbers which are growing at a miniscule pace weekly. As to this current thread, I'm seeking the boards thoughts about the possibility of life after Sanofi, should that occur. It's clear from my comments that I'm thinking maybe we'd be better off without Sanofi (so far I'm very unimpressed with Sanofi). Of course it would require that Al Mann bring in a whole new management team to lead a new charge. As you can tell I'm not real bullish on the stock but I haven't sold a share, nor have I bought any shares at these low prices. I agree with the other posters who have said that the next few months are critically important to the Company and I hope I am wrong about Sanofi. Trend Trend Thanks for the clear, forthright answer. I disagree with your assessment of Sanofi, but I think I understand why you would hold the view you do. We do agree that the next few months may likely be very important and very revealing about the future prospects of this drug. We also seem to share the same strategy. I have not sold shares, I too am disappointed in the share price, and I have a self-imposed moratorium on the purchase of additional shares until scripts begin to show an uptick. Sometimes it seems as though positive developments for this company are in slow motion, which of course gives shorts more ammunition than they need. It is also worth mentioning that since half of the float is held short, there is a stranglehold on upward movement. Regards Chris C |
|
|
|
Post by suebeeee1 on Aug 21, 2015 1:31:57 GMT -5
Everyone knows that I'm long with almost everyone here. We all are feeling some stress because of sales and what seems to be less interest & effort by Sanofi than we think our truly amazing new drug deserves. There are days that I wonder whether or not Sanofi bought the rights in order to just put it on the shelf. Or I worry that the new CEO, who has experience with that failed inhalable payday product, will just ditch a deal that preceded his term.
But then something happens which allows me to continue to feel comfortable with my position long term. I see, foe example how Sanofi presented Afrezza art the national ADA conference or the beginning of a print add series in one of the biggest"waiting room" magazines in our country.
Sigh... This is indeed a marathon and in an age on instant gratification, it may be longer than we feel happy about. But we have a product and a company with an incredible technology: Technosphere. Without cash, MNKD can't work to put anything in the pipeline. Without Sanofi, there isn't enough to launch Afrezza much less expand research for another product.;
I
|
|
|
|
Post by BlueCat on Aug 21, 2015 1:46:52 GMT -5
I did have concerns about the new CEO - and whether the real deal was struck with the previous, or with the board. That would make a difference. CEOs always move to put their own team and hands on the business. How else can they take credit for success and justify their jobs? They often reinvent wheels that are rolling just fine.
But I still think SNY is actually handling this the right way. A blockbuster business takes work to build. And they are putting all the pieces in place. Building a strong foundation.
|
|
